NAOV Stock Overview
Through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NanoVibronix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.64 |
| 52 Week High | US$1.52 |
| 52 Week Low | US$0.46 |
| Beta | 1.51 |
| 11 Month Change | 15.82% |
| 3 Month Change | 10.78% |
| 1 Year Change | -53.16% |
| 33 Year Change | -97.35% |
| 5 Year Change | -98.88% |
| Change since IPO | -99.09% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable
Dec 09
NanoVibronix receives extension to satisfy Nasdaq bid price requirement
Oct 19NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract
Sep 23Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?
Jul 08Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?
Mar 22Is NanoVibronix (NASDAQ:NAOV) In A Good Position To Deliver On Growth Plans?
Dec 01NanoVibronix: Portable Ultrasonic Therapeutic Devices
Sep 01NanoVibronix (NASDAQ:NAOV) Is In A Good Position To Deliver On Growth Plans
Aug 17NanoVibronix announces expansion of distribution pact for its ultrasound devices
Dec 11NanoVibronix secures $6M in equity capital
Dec 02NanoVibronix reports Q3 results
Nov 17Shareholder Returns
| NAOV | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.9% | -0.8% | -1.2% |
| 1Y | -53.2% | 20.9% | 30.4% |
Return vs Industry: NAOV underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: NAOV underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| NAOV volatility | |
|---|---|
| NAOV Average Weekly Movement | 12.5% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NAOV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NAOV's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 13 | Brian Murphy | www.nanovibronix.com |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company’s product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.
NanoVibronix, Inc. Fundamentals Summary
| NAOV fundamental statistics | |
|---|---|
| Market cap | US$2.39m |
| Earnings (TTM) | -US$3.09m |
| Revenue (TTM) | US$3.29m |
0.7x
P/S Ratio-0.8x
P/E RatioIs NAOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAOV income statement (TTM) | |
|---|---|
| Revenue | US$3.29m |
| Cost of Revenue | US$1.33m |
| Gross Profit | US$1.96m |
| Other Expenses | US$5.05m |
| Earnings | -US$3.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.82 |
| Gross Margin | 59.62% |
| Net Profit Margin | -93.80% |
| Debt/Equity Ratio | 0% |
How did NAOV perform over the long term?
See historical performance and comparison